A Retrospective Study of Glucagon-Like Peptide  1 Receptor Agonists for the Management of Diabetes After Transplantation
ConclusionsOur data suggest that GLP-1RA do not affect tacrolimus levels or transplant outcomes in solid organ transplant (SOT) recipients in the short term. GLP-1RA also seem to be as effective in SOT recipients for glycemic control and weight loss as in the non-transplant population with diabetes. (Source: Diabetes Therapy)
Source: Diabetes Therapy - February 18, 2020 Category: Endocrinology Source Type: research

Development and Validation of a New Diabetes Risk Score in Guyana
ConclusionsThe validated eight-item Guyana Diabetes Risk Score will be extremely useful in identifying individuals at high risk of having diabetes in Caribbean, Black or East Indian populations. (Source: Diabetes Therapy)
Source: Diabetes Therapy - February 18, 2020 Category: Endocrinology Source Type: research

Diabetic Neuropathy Collection: Introduction to Diabetic Neuropathy
Introduction to Diabetic Neuropathy podcast recording (MP4 55526 kb) (Source: Diabetes Therapy)
Source: Diabetes Therapy - February 17, 2020 Category: Endocrinology Source Type: research

Comparison of the Efficacy and Safety of Rosuvastatin/Ezetimibe Combination Therapy and Rosuvastatin Monotherapy on Lipoprotein in Patients With Type 2 Diabetes: Multicenter Randomized Controlled Study
AbstractIntroductionEzetimibe/statin combination therapy has been reported to provide additional cardioprotective effects compared to statin monotherapy. The apolipoprotein B/A1 (apoB/A1) ratio is an effective predictor of cardiovascular diseases. The aim of this study was to compare the efficacy and safety of rosuvastatin/ezetimibe combination therapy versus rosuvastatin monotherapy using the apoB/A1 ratio in patients with diabetes and hypercholesterolemia.MethodsIn this randomized, multicenter, open-label, parallel-group study, patients were randomly assigned to receive the combination therapy of rosuvastatin 5  mg/...
Source: Diabetes Therapy - February 17, 2020 Category: Endocrinology Source Type: research

Evaluation of Glycaemic Control, Glucose Variability and Hypoglycaemia on Long-Term Continuous Subcutaneous Infusion vs. Multiple Daily Injections: Observational Study in Pregnancies With Pre-Existing Type 1 Diabetes
AbstractIntroductionWe evaluated the effectiveness of long-term continuous subcutaneous insulin infusion (CSII) compared with multiple daily insulin (MDI) injections for glycaemic control and variability, hypoglycaemic episodes and maternal/neonatal outcomes in pregnant women with pre-existing type 1 diabetes (pT1D).MethodsOur observational cohort study included 128 consecutive pregnant women with pT1D, who were treated from 1 January 2010 to 31 December 2017. Of 128 participants, 48 were on CSII and 80 were on MDI. Glycaemic control was determined by glycated haemoglobin (HbA1c) (captured in preconception and each trimest...
Source: Diabetes Therapy - February 15, 2020 Category: Endocrinology Source Type: research

SGLT2 Inhibitors and the Risk of Hospitalization for Fournier ’s Gangrene: A Nested Case–Control Study
ConclusionThe study did not find that treatment with SGLT2i, as compared with treatment with two or more non-SGLT2i AHAs or insulin alone, was statistically significantly associated with an increased risk of hospitalization for FG. Additional studies are needed to corroborate the findings. (Source: Diabetes Therapy)
Source: Diabetes Therapy - February 12, 2020 Category: Endocrinology Source Type: research

Correction to: Study Protocol for the Effects of Formula Diet with Dapagliflozin on Metabolic Improvement and Body Composition in Type 2 Diabetes Mellitus
In the original article, the 6th sentence of the section “FD and calorie intake” is incorrect. The correct sentence is “The protein component of FD consists of whey protein, casein, and soy protein”. (Source: Diabetes Therapy)
Source: Diabetes Therapy - February 12, 2020 Category: Endocrinology Source Type: research

Acute Complications of Diabetes Among Pilgrims During Hajj 2017: A Brief Report
ConclusionThe most common acute complication of diabetes during Hajj is foot injury. Pilgrims who suffered from hyperglycemia presented mainly with polydipsia, while those who developed hypoglycemia presented mainly with fatigue. There was no statistically significant difference according to the association between the type of diabetes and the occurrence of acute complications. (Source: Diabetes Therapy)
Source: Diabetes Therapy - February 8, 2020 Category: Endocrinology Source Type: research

Efficacy of Vildagliptin Added to Continuous Subcutaneous Insulin Infusion (CSII) in Hospitalized Patients with Type 2 Diabetes
AbstractIntroductionThe aim of this study was to compare the efficacy of vildagliptin as add-on therapy to short-term continuous subcutaneous insulin infusion (CSII) with CSII monotherapy in hospitalized patients with type 2 diabetes mellitus (T2DM).MethodsA total of 200 hospitalized patients with inadequately controlled T2DM were randomized into groups, with one group receiving CSII monotherapy (CSII group,n =100) and the other group receiving CSII plus vildagliptin as add-on (CSII + Vig group,n = 100). Of these, 191 completed the 7-day trial (CSII group,n = 99; CSII&thinsp...
Source: Diabetes Therapy - February 4, 2020 Category: Endocrinology Source Type: research

Best Practices and Tools for Titrating Basal Insulins: Expert Opinion from an Indian Panel via the Modified Delphi Consensus Method
ConclusionsIn the management of T2DM, insulin can be effectively titrated by following a few simple recommendations. The use of second-generation basal insulin aids in mitigating the risk of hypoglycemic events. The implementation of a simplified titration regimen is crucial to achieving glycemic targets and long-term treatment goals. (Source: Diabetes Therapy)
Source: Diabetes Therapy - February 3, 2020 Category: Endocrinology Source Type: research

Application of Machine Learning Models to Evaluate Hypoglycemia Risk in Type  2 Diabetes
AbstractIntroductionTo identify predictors of hypoglycemia and five other clinical and economic outcomes among treated patients with type  2 diabetes (T2D) using machine learning and structured data from a large, geographically diverse administrative claims database.MethodsA retrospective cohort study design was applied to Optum Clinformatics claims data indexed on first antidiabetic prescription date. A hypothesis-free, Bayesian machine learning analytics platform (GNS Healthcare REFS ™: Reverse Engineering and Forward Simulation) was used to build ensembles of generalized linear models to predict six outcomes ...
Source: Diabetes Therapy - February 3, 2020 Category: Endocrinology Source Type: research

Effectiveness of a Video-Based Lifestyle Education Program Compared to Usual Care in Improving HbA1c and Other Metabolic Parameters in Individuals with Type 2 Diabetes: An Open-Label Parallel Arm Randomized Control Trial (RCT)
ConclusionThe VBLEP demonstrated a significant and clinically relevant HbA1c reduction compared with usual care. A simple VBLEP, when delivered in an interactive manner, can aid in improving glycemic outcomes in the Indian population.Trial RegistrationCTRI/2017/05/008564. (Source: Diabetes Therapy)
Source: Diabetes Therapy - January 31, 2020 Category: Endocrinology Source Type: research

Association of Hemoglobin A1c, 1,5-Anhydro- d -Glucitol and Glycated Albumin with Oxidative Stress in Type 2 Diabetes Mellitus Patients: A Cross-Sectional Study
AbstractIntroductionOxidative stress plays a central role in the development and progression of vascular complications in patients with type 2 diabetes mellitus (T2DM). We have previously shown that markers of glucose variability evaluated by continuous glucose monitoring (CGM) are positively associated with oxidative stress in patients with T2DM. However, the evaluation of the glycemic variability by CGM remains a time- and money-consuming procedure. Therefore, this study investigated the independent correlates of oxidative stress among various other clinical markers routinely measured in primary care.MethodsThis was a re...
Source: Diabetes Therapy - January 29, 2020 Category: Endocrinology Source Type: research

Efficacy and Safety of Once-Weekly Dulaglutide in Type 2 Diabetes Patients Using Insulin: Exploratory Subgroup Analysis by Insulin Regimen
AbstractPurposeIn East Asian patients, type 2 diabetes mellitus (T2DM) is characterized primarily by β-cell dysfunction, with lower insulin secretion than in Caucasian individuals. Therefore, bolus insulin and premixed insulin containing a bolus insulin component are important therapeutic tools in Japan, in addition to basal insulin. This subgroup analysis is stratified by insulin regimen and uses data from a phase 4, randomized, placebo-controlled, double-blind and subsequent open-label study in Japan to assess the efficacy and safety of once-weekly dulaglutide combined with various insulin therapies.MethodsThis mult...
Source: Diabetes Therapy - January 29, 2020 Category: Endocrinology Source Type: research

Efficacy and Safety of Treatment with New Basal Insulin Analogues in Type 1 Diabetes: Nation-Wide Survey
ConclusionThe long-term effects and safety of IG300 and ID appear to be very similar in adult patients with type 1 diabetes. The results of this study suggest that these basal insulin analogues may provide benefits compared with the established reference IG100. (Source: Diabetes Therapy)
Source: Diabetes Therapy - January 28, 2020 Category: Endocrinology Source Type: research

Smartphone-Based Technology in Diabetes Management
AbstractDiabetes is a group of metabolic disorders characterized by elevated levels of blood glucose which leads over time to serious complications and significant morbidity and mortality worldwide. Self-management tasks in diabetes may be quite challenging because of lack of training, difficulties in sustaining lifestyle modifications, and limited access to specialized healthcare. Nowadays, the evolution of mobile technology provides a large number of health-related smartphone applications (apps), aiming to increase the self-management skills of the patient in chronic diseases, to facilitate the communication between the ...
Source: Diabetes Therapy - January 25, 2020 Category: Endocrinology Source Type: research

A Practitioner ’s Toolkit for Insulin Motivation in Adults with Type 1 and Type 2 Diabetes Mellitus: Evidence-Based Recommendations from an International Expert Panel
ConclusionsIn the management of DM, bringing in positive behavioral change by motivating the patient to improve treatment adherence helps overcome insulin distress and achieve treatment goals. (Source: Diabetes Therapy)
Source: Diabetes Therapy - January 24, 2020 Category: Endocrinology Source Type: research

The Effect of LM25 and LM50 on Hypoglycemia in Chinese T2DM Patients: Post Hoc Analysis of a Randomized Crossover Trial
ConclusionsThe risk of nocturnal hypoglycemia in the LM50 regimen was lower than that in the LM25 regimen under the HCD pattern, and the safety range of bedtime glucose for the LM50 regimen was wider than that of the LM25 regimen in Chinese T2DM patients. Premixed insulin analogs combined with acarbose were more helpful to reduce the incidence of hypoglycemia.Trial Registrationhttp://www.chictr.org.cn #ChiCTR-TTRCC-12002516. (Source: Diabetes Therapy)
Source: Diabetes Therapy - January 24, 2020 Category: Endocrinology Source Type: research

Study Protocol for Pleiotropic Effects and Safety of Sodium –Glucose Cotransporter 2 Inhibitor Versus Sulfonylurea in Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
This study is a 48-week, one-center (only Kanazawa University Hospital), open-label, randomized, parallel trial. Patients who satisfied the eligibility criteria were randomly assigned (1:1) to receive once-daily 20  mg tofogliflozin or 0.5 mg glimepiride. The sample size was calculated to be 14 in each group with a significance level of 0.05 and power of 0.90. The design required 40 evaluable patients in this study. The primary endpoint of this study will be the improvement in liver histology between liver b iopsies at baseline and after 48 weeks of treatment. The secondary efficacy endpoints in the present ...
Source: Diabetes Therapy - January 20, 2020 Category: Endocrinology Source Type: research

Metformin Delays the Development of Atherosclerosis in Type 1 Diabetes Mellitus Via the Methylglyoxal Pathway
ConclusionsMetformin can limit the development of atherosclerosis secondary to diabetes in young diabetic mice. A possible mechanism is the removal of methylglyoxal, thereby reducing the formation of advanced glycation endproducts, rather than by lowering the blood glucose level.FundingThis work was supported by the National Natural Science Foundation of China (81901106) and Jinan clinical medical science and technology innovation plan (201907002). (Source: Diabetes Therapy)
Source: Diabetes Therapy - January 18, 2020 Category: Endocrinology Source Type: research

Cost of Managing Type  2 Diabetes Before and After Initiating Dipeptidyl Peptidase 4 Inhibitor Treatment: A Longitudinal Study Using a French Public Health Insurance Database
ConclusionDespite an initial increase in healthcare expenditure, concomitant with reevaluation of patient care, this study showed that initiation of DPP4Is as an add-on therapy in French patients with T2D was associated with care expenditure that was in line or below predicted values within the 3  years following treatment initiation. Additional studies are required to evaluate the economic impact of the long-term treatment benefits. (Source: Diabetes Therapy)
Source: Diabetes Therapy - January 17, 2020 Category: Endocrinology Source Type: research

Long-Term Safety and Effectiveness of Linagliptin in Japanese Patients with Type 2 Diabetes and Renal Dysfunction: a Post-Marketing Surveillance Study
AbstractIntroductionInternational clinical trials have shown that linagliptin significantly improves glycemic control and can be used at a single dose regardless of renal function in patients with type 2 diabetes (T2D). However, to date, no studies have evaluated the use of linagliptin in Japanese patients with T2D by renal function in routine clinical care.MethodsThis was a subgroup analysis of data from a prospective observational post-marketing surveillance (PMS) study of linagliptin conducted in Japan that evaluated the safety and effectiveness of linagliptin in routine clinical care for 3  years in Japanese patie...
Source: Diabetes Therapy - January 13, 2020 Category: Endocrinology Source Type: research

Commentary to “Differential Effect of Hypoalbuminemia on Hypoglycemia on Type 2 Diabetes Patients Treated with Insulin Glargine 300 U/ml and Insulin Degludec” by Kawaguchi et al. Diabetes Therapy 2019
(Source: Diabetes Therapy)
Source: Diabetes Therapy - January 10, 2020 Category: Endocrinology Source Type: research

The Short-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin and Once-Weekly Dulaglutide for the Treatment of Patients with Type  2 Diabetes: A Cost of Control Analysis in Spain
This study assessed the cost of bringing patients with type 2 diabetes to three clinically relevant e ndpoints with semaglutide versus sitagliptin and dulaglutide in Spain.MethodsThe proportions of patients achieving endpoints of HbA1c  
Source: Diabetes Therapy - January 10, 2020 Category: Endocrinology Source Type: research

Impact of Switching from Twice-Daily Basal Insulin to Once-Daily Insulin Glargine 300  U/mL in People with Type 1 Diabetes on Basal–Bolus Insulin: Phase 4 OPTIMIZE Study
AbstractIntroductionOPTIMIZE evaluated the efficacy, safety and treatment satisfaction of insulin glargine 300  U/mL once daily (Gla-300 OD) in people with type 1 diabetes mellitus (T1DM) previously uncontrolled on basal insulin twice daily (BID) as part of basal–bolus therapy.MethodsOPTIMIZE was a 28-week, prospective, interventional, single-arm phase  4 trial in adults with T1DM. At baseline, basal insulin BID treatment was switched to Gla-300 OD titrated to a fasting self-monitored blood glucose target of 4.4–7.2 mmol/L (80–130 mg/dL). The primary endpoint was the mean glycated...
Source: Diabetes Therapy - January 10, 2020 Category: Endocrinology Source Type: research

Utility of Precision Medicine in the Management of Diabetes: Expert Opinion from an International Panel
ConclusionPrecision medicine opens new vistas for the effective use of SUs in unexpected patient populations, such as those with genetic mutations. (Source: Diabetes Therapy)
Source: Diabetes Therapy - January 8, 2020 Category: Endocrinology Source Type: research

Adherence to Medication, Diet and Physical Activity and the Associated Factors Amongst Patients with Type  2 Diabetes
AbstractIntroductionThe prevalence of type  2 diabetes mellitus (T2D) has increased considerably while the outcome of diabetic management is suboptimal. In order to promote diabetic management, associated factors for adherence to medications, diet, and physical activity (PA) need to be more clearly identified amongst patients with T2D.MethodsThis cross-sectional study was conducted on 206 men and 294 women amongst patients with diabetes who were registered in ten special diabetic clinics in Shiraz, Iran from November 2018 to April 2019. Levels of adherence to medication, Mediterranean diet (MD), and physical activity ...
Source: Diabetes Therapy - January 8, 2020 Category: Endocrinology Source Type: research

Insulin Therapy in Adults with Type 1 Diabetes Mellitus: a Narrative Review
AbstractHere, we review insulin management options and strategies in nonpregnant adult patients with type 1 diabetes mellitus (T1DM). Most patients with T1DM should follow a regimen of multiple daily injections of basal/bolus insulin, but those not meeting individual glycemic targets or those with frequent or severe hypoglycemia or pronounced dawn phenomenon should consider continuous subcutaneous insulin infusion. The latter treatment modality could also be an alternative based on patient preferences and availability of reimbursement. Continuous glucose monitoring may improve glycemic control irrespective of treatment reg...
Source: Diabetes Therapy - January 4, 2020 Category: Endocrinology Source Type: research

Insulin Glargine 300  U/mL and Insulin Glulisine Treatment in Patients with Type 2 Diabetes: A Non-Interventional Study of Effectiveness in Routine Clinical Practice
ConclusionsIn day-to-day practice, switching from human insulin to Gla-300-based BBT resulted in significant improvement in glycemic control and decrease in hypoglycemia risk. (Source: Diabetes Therapy)
Source: Diabetes Therapy - January 3, 2020 Category: Endocrinology Source Type: research

Familial Hypercholesterolaemia in a Bulgarian Population of Patients with Dyslipidaemia and Diabetes: An Observational Study
AbstractIntroductionPatients with diabetes and familial hypercholesterolaemia (FH) are at very high risk of cardiovascular events, but rates of FH detection are very low in most countries, including Bulgaria. Given the lack of relevant data in the literature, we conducted a retrospective observational study to (1) identify individuals with previously undiagnosed FH among patients being treated at Bulgarian diabetes centres, and (2) gain insight into current management and attainment of low-density lipoprotein cholesterol (LDL-C) goals in such patients.MethodsFrom a database of diabetes centres across Bulgaria we retrieved ...
Source: Diabetes Therapy - January 2, 2020 Category: Endocrinology Source Type: research

IDegLira Improves Glycemic Control in Japanese Patients with Uncontrolled Type 2 Diabetes on Premixed Insulin Therapy
ConclusionThis post hoc study is the first to evaluate the switch from premixed insulin to IDegLira in patients with uncontrolled T2D. IDegLira initiation resulted in improved HbA1c and weight loss. This study offers insight into the effectiveness and safety of switching patients from premixed insulin therapy to IDegLira, and provides support for further investigation.Trial RegistrationNCT02911948. (Source: Diabetes Therapy)
Source: Diabetes Therapy - January 1, 2020 Category: Endocrinology Source Type: research

Patient Preferences and Health State Utilities Associated with Mealtime Insulin Concentrations Among Patients with Diabetes in Italy
AbstractIntroductionStandard concentration (100 units/mL) mealtime insulin is frequently used to treat patients with type 1 (T1D) and type 2 diabetes (T2D). A more concentrated version of the medication (200 units/mL) has been available in Italy since 2016. This concentrated version is bioequivalent to the standard version and delivers the same amount of medication but in half the volume of liquid. The purpose of this study was to examine patient preferences and estimate health state utilities associated with standard and concentrated rapid-acting mealtime analog insulin.MethodsParticipants with T1D and T2D in Italy valued...
Source: Diabetes Therapy - January 1, 2020 Category: Endocrinology Source Type: research

Efficacy and Safety of Switching Patients Inadequately Controlled on Basal Insulin to Insulin Glargine 300  U/mL: The TRANSITION 2 Study
This study aimed to determine, in close to real-life conditions, the efficacy and safety of switching from any basal insulin to insulin glargine 300  U/mL (Gla-300) in patients with uncontrolled type 2 diabetes (T2D).MethodsThis was an interventional, multicenter, single-arm, prospective study with a 24-week treatment phase. Adult patients with T2D treated with basal insulin with or without other antidiabetics, HbA1c  >  7.5%, and fasting self-monitored blood glucose (F-SMBG) >  130 mg/dL (mean of three measures) at baseline were included. Insulin dose was titrated to reach F-SMB...
Source: Diabetes Therapy - January 1, 2020 Category: Endocrinology Source Type: research

Experiences of Attending Group Education to Support Insulin Initiation in Type 2 Diabetes: A Qualitative Study
ConclusionPositive experiences of insulin group education for people with type 2 diabetes were associated with sharing experiences with other people starting insulin, reassurance from healthcare professionals, appropriate supportive materials, and skill of the facilitator to address insulin concerns and manage group dynamics. People with type 2 diabetes may benefit more from education if healthcare professionals are skilled in psychological techniques to facilitate group education aimed at addressing concerns around insulin therapy. Further research needs to assess the effectiveness of structured insulin group education fo...
Source: Diabetes Therapy - January 1, 2020 Category: Endocrinology Source Type: research

Correction to: Optimising the Benefits of SGLT2 Inhibitors for Type 1 Diabetes
In the original article, Associated Medical Education Section has been published mistakenly. It has been removed from the original publication. (Source: Diabetes Therapy)
Source: Diabetes Therapy - December 31, 2019 Category: Endocrinology Source Type: research

Clinical Inertia in Poorly Controlled Type 2 Diabetes Mellitus Patients with Obesity: An Observational Retrospective Study
ConclusionsThe patients with T2DM analysed in this study had a mean HbA1c of 9.2% at baseline, and this remained at ≥ 8% for> 1 year. The time to the first treatment intensification was longer than that recommended by guidelines. Treatment was not intensified in a large percentage of patients, with almost 60% of patients not receiving intensification at 1  year of follow-up. (Source: Diabetes Therapy)
Source: Diabetes Therapy - December 28, 2019 Category: Endocrinology Source Type: research

Rapid-Acting Insulin Analogues Versus Regular Human Insulin: A Meta-Analysis of Effects on Glycemic Control in Patients with Diabetes
AbstractIntroductionThe aim of this meta-analysis was to investigate the impact of rapid-acting insulin analogues (RAIAs) and regular human insulin (RHI) on glycemic control, including long- and short-term glycemic variability as measured by glycated haemoglobin (HbA1c) and pre- and postprandial glucose (PPG).MethodsPubMed was searched for studies published between 1999 and 29 June 2016. Randomised controlled trials of patients with diabetes that assessed the effects of RAIAs or RHI on glycemic control, focusing on preprandial glucose, PPG and HbA1c, were included. Only studies that reported both means and standard deviati...
Source: Diabetes Therapy - December 23, 2019 Category: Endocrinology Source Type: research

Correction to: The Association Between Phosphorylated Neurofilament Heavy Chain (pNF-H) and Small Fiber Neuropathy (SFN) in Patients with Impaired Glucose Tolerance
In the original article, there was some error in Table  2. The correct table is given below. (Source: Diabetes Therapy)
Source: Diabetes Therapy - December 21, 2019 Category: Endocrinology Source Type: research

Renal Outcomes in Type 2 Diabetes: A Review of Cardiovascular and Renal Outcome Trials
This article explores some of the possible mechanisms by which these drugs may improve renal function in people with diabetes, and it reviews important CVOTs that have reported renal outcomes to date. These include CVOTS of sodium-glucose cotransporter-2 inhibitors (EMPA-REG OUTCOME study, CANVAS study, CREDENCE trial, DECLARE-TIMI trial and DAPA-HF study), dipeptidyl peptidase-4 inhibitors (EXAMINE trial, SAVOR-TIMI 53, TECOS trial and CARMELINA trial) and glucagon-like peptide-1 analogues (ELIXA trial, LEADER trial, SUSTAIN-6 trial, PIONEER-6 trial, EXSCEL trial, HARMONY Outcomes study and the REWIND study). Ongoing card...
Source: Diabetes Therapy - December 20, 2019 Category: Endocrinology Source Type: research

A Multinational Real-World Study on the Clinical Characteristics of Patients with Type  2 Diabetes Initiating Dapagliflozin in Southern Europe
AbstractIntroductionA real-world study was performed to describe the clinical characteristics of patients who received dapagliflozin to better understand differences when initiating dapagliflozin in various countries and different prescribing settings.MethodsWe assessed pooled data from observational studies carried out in Italy (n = 2484), Spain (n = 564) and Greece (n = 87). The primary objective was to compare the clinical profile of patients initiating dapagliflozin in the three countries. We also evaluated the percentage of patients who received dapagliflozin in clinical pract...
Source: Diabetes Therapy - December 20, 2019 Category: Endocrinology Source Type: research

Efficacy and Safety of iGlarLixi, Fixed-Ratio Combination of Insulin Glargine and Lixisenatide, Compared with Basal-Bolus Regimen in Patients with Type  2 Diabetes: Propensity Score Matched Analysis
AbstractIntroductionBasal-bolus (BB) regimens are generally used to intensify basal insulin therapy in patients with type  2 diabetes (T2D) not meeting glycemic targets. However, drawbacks include multiple injection burden and risk of weight gain and hypoglycemia. A once-daily titratable fixed-ratio combination of insulin glargine 100 U/mL and lixisenatide (iGlarLixi) may provide a simple, well-tolerated, and efficac ious alternative. We compared these treatments in a post hoc propensity score matched analysis using randomized trial data.MethodsFrom the LixiLan-L study, 195 patients who had been randomized to iGl...
Source: Diabetes Therapy - December 17, 2019 Category: Endocrinology Source Type: research

Measurement Uncertainty Impacts Diagnosis of Diabetes Mellitus: Reliable Minimal Difference of Plasma Glucose Results
ConclusionImprecision as measured by IQC data is remarkably stable over many years of operation. Current imprecision assessment usually focuses on only single instruments, whereas clinicians perceive the measurement as the result of the combined analytical performance of all instruments used for a certain assay. In the clinical setting, the MD may be a more useful measure of imprecision, and we suggest deriving the MDcut-off combined from all instruments and control cycles that are used in the patient care setting for a given analyte. (Source: Diabetes Therapy)
Source: Diabetes Therapy - December 16, 2019 Category: Endocrinology Source Type: research

Oral Semaglutide Versus Empagliflozin, Sitagliptin and Liraglutide in the UK: Long-Term Cost-Effectiveness Analyses Based on the PIONEER Clinical Trial Programme
ConclusionOral semaglutide was cost-effective versus empagliflozin and sitagliptin, and dominant versus liraglutide, for the treatment of type 2 diabetes in the UK. (Source: Diabetes Therapy)
Source: Diabetes Therapy - December 12, 2019 Category: Endocrinology Source Type: research

Three European Retrospective Real-World Chart Review Studies to Determine the Effectiveness of Flash Glucose Monitoring on HbA1c in Adults with Type  2 Diabetes
AbstractIntroductionThe impact of flash glucose monitoring technology on HbA1c in type  2 diabetes managed by basal bolus insulin is uncertain. Three parallel European retrospective non-interventional chart review studies collected data reported in medical records. Each country’s study aim was to determine the effectiveness of the device on HbA1c when used by their population for 3 –6 months as their standard of care for management of glycaemia in a real-world setting.MethodsMedical records were eligible for adult patients with type  2 diabetes, on a basal bolus insulin regimen for 1 year or...
Source: Diabetes Therapy - December 12, 2019 Category: Endocrinology Source Type: research

Vildagliptin Versus α-Glucosidase Inhibitor as Add-On to Metformin for Type 2 Diabetes: Subgroup Analysis of the China Prospective Diabetes Study
AbstractIntroductionThe effect of dipeptidyl peptidase-4 (DDP-4) inhibitors versus α-glucosidase inhibitors (AGIs) on the treatment of type 2 diabetes mellitus (T2DM) in a real-world setting is unknown. The aim of this real-world study was to compare the glucose-lowering effect and tolerability of vildagliptin as add-on to metformin monotherapy (VM) and AGI as add-on to metformin monotherapy (AM) in Chinese patients with T2DM.MethodsThis was a subgroup analysis of the China Prospective Diabetes Study, a post-marketing, prospective, observational, real-world study conducted at 52 centers in China. T2DM patients with i...
Source: Diabetes Therapy - December 10, 2019 Category: Endocrinology Source Type: research

Real-world Effectiveness of Liraglutide vs. Sitagliptin Among Older Patients with Type 2 Diabetes Enrolled in a Medicare Advantage Prescription Drug Plan: A Retrospective Observational Study
AbstractIntroductionLiraglutide and sitagliptin were compared on glycemic control and all-cause healthcare costs over a 1-year period among older adults with type 2 diabetes (65 –89 years) enrolled in a national Medicare Advantage Prescription Drug health plan.MethodsThis was a retrospective study in which the index date was the first prescription fill for liraglutide or sitagliptin between 25 January 2010 and 31 December 2014. Post-index treatment persistence and glycosylated hemoglobin (HbA1c) at baseline and 1  year (± 90 days) post-index date were required. Patients were excluded if t...
Source: Diabetes Therapy - December 9, 2019 Category: Endocrinology Source Type: research

Optimising the Benefits of SGLT2 Inhibitors for Type 1 Diabetes
AbstractSodium-glucose cotransporter 2 (SGLT2) inhibitor clinical studies in type 1 diabetes mellitus (T1DM) have demonstrated reduced HbA1c and lower glucose variability with increased time in optimal glucose range as well as additional benefits of reductions in weight and insulin dose without increasing the incidence of hypoglycaemia. However, the appropriate use of SGLT2 inhibitor therapies within clinical practise to treat people with T1DM remains unclear. In this article we have used consensus expert opinion alongside the available evidence, product indication and most recent clinical guidance to provide support for t...
Source: Diabetes Therapy - December 7, 2019 Category: Endocrinology Source Type: research

Metabolic Control and Adherence to Therapy in Type 2 Diabetes Mellitus Patients Using IDegLira in a Real-World Setting
AbstractIntroductionInsulin degludec/liraglutide (IDegLira) is a fixed-ratio combination (FRC) of basal insulin and glucagon-like protein-1 receptor agonist (GLP-1 RA) that has demonstrated glycemic and metabolic benefits in patients with type 2 diabetes mellitus (T2DM) in both randomized controlled trials and real-world studies. The impact of adherence to this medication and its effect on patients with T2DM who switch from loose-dose combination therapy to a FRC of insulin and GLP-1RA have not yet been reported. We have examined the metabolic effects and adherence to this medication in a real-life setting, in T2DM patient...
Source: Diabetes Therapy - December 5, 2019 Category: Endocrinology Source Type: research

Comparative Effects of Three Kinds of Bariatric Surgery: A Randomized Case –Control Study in Obese Patients
ConclusionThis study suggests that bariatric surgery is only a prerequisite for weight loss, and the long-term dietary control and exercise can help patients achieve optimal weight loss. (Source: Diabetes Therapy)
Source: Diabetes Therapy - December 3, 2019 Category: Endocrinology Source Type: research

Insulin Resistance in Type 1 Diabetes Mellitus and Its Association with Patient ’s Micro- and Macrovascular Complications, Sex Hormones, and Other Clinical Data
AbstractIntroductionThe main objective of this research was to evaluate the association of insulin resistance (IR) with micro- and macrovascular complications, sex hormones, and other clinical data.MethodsCross-sectional study of patients older than 18  years old with type 1 diabetes mellitus (T1DM) was performed. Participants filled in questionnaires about T1D, disease duration, smoking, glycemic control, chronic diabetes complications, and hypertension status. Data about chronic diabetic complications (neuropathy, retinopathy, and nephropathy) were collected from medical records. History of major cardiovascular even...
Source: Diabetes Therapy - December 2, 2019 Category: Endocrinology Source Type: research